SWOG S1400E

Primary Category:

Treatment Protocols

Disease Category:

Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling

Status:

Closed

A Phase II/III Randomized Study of Rilotumumab Plus Erlotinib Versus Erlotinib as Second Line Therapy for C-MET Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)

 

(See required screening study SWOG S1400)

NCT#02154490

Leave a Reply